Serum IGF-1 determination in relation to prostate cancer screening: Possible differential diagnosis in relation to PSA assays

Prostate Cancer and Prostatic Diseases

Volumn 3, Issue 3, 2000, Pages 173-175

  Turkes, A ^a   Peeling, W B ^b   Griffiths, K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Prostate cancer; PSA; Screening; Serum IGF 1

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

EID: 0033637141     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500417     Document Type: Article

References (8)

1. Effect of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells
2. The insulin-like growth factor system in the prostate
3. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
4. Insulin-like growth factors and their binding proteins: Biological actions
5. Growth, differentiation and survival: Multiple physiological functions for insulin-like growth factors
6. Insulin-like growth factor-1 and new opportunities for cancer prevention
7. Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study
8. Screening and early detection of prostate cancer